Novartis Japan Gets Asthma Drug Xolair Approved For Child Use
This article was originally published in PharmAsia News
Executive Summary
Novartis Japan obtained approval for an additional indication of its 75mg and 150mg subcutaneous injection Xolair (omalizumab) for pediatric bronchial asthma treatment.